CN Patent

CN120441536A — 大规模制备化合物半琥珀酸盐和乙酸盐的方法和中间体

Assigned to Eli Lilly and Co · Expires 2025-08-08 · 1y expired

What this patent protects

本发明的实施方案提供了大规模制备2,4,6‑三氟‑N‑[6‑(1‑甲基哌啶‑4‑羰基)‑2‑吡啶基]苯甲酰胺半琥珀酸盐的方法和中间体，以及通过这些方法制备的制剂和产品形式。本发明的实施方案进一步提供了拉司米地坦乙酸盐(2,4,6‑三氟‑N‑[6‑(1‑甲基哌啶‑4‑羰基)‑2‑吡啶基]苯甲酰胺乙酸盐)和/或其药物组合物的制备，和/或拉司米地坦乙酸盐及其制剂在皮下药物递送中的用途。

USPTO Abstract

本发明的实施方案提供了大规模制备2,4,6‑三氟‑N‑[6‑(1‑甲基哌啶‑4‑羰基)‑2‑吡啶基]苯甲酰胺半琥珀酸盐的方法和中间体，以及通过这些方法制备的制剂和产品形式。本发明的实施方案进一步提供了拉司米地坦乙酸盐(2,4,6‑三氟‑N‑[6‑(1‑甲基哌啶‑4‑羰基)‑2‑吡啶基]苯甲酰胺乙酸盐)和/或其药物组合物的制备，和/或拉司米地坦乙酸盐及其制剂在皮下药物递送中的用途。

Drugs covered by this patent

lasmiditan-succinate (LASMIDITAN SUCCINATE)

Patent Metadata

Patent number: CN120441536A
Jurisdiction: CN
Classification: —
Expires: 2025-08-08
Drug substance claim: No
Drug product claim: No
Assignee: Eli Lilly and Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.